Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-   People with diabetes are two times more likely to become infected with the hepatitis B virus (HBV) and up to four times as likely to get HBV-related liver cancer

Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?

Gilead Sciences

Eli Lilly

Moderna

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

This stock has the potential to break new highs with its key hepatitis B vaccine and emerging vaccine-adjuvant platform for COVID-19 vaccines.

Is Dynavax Technologies Stock a Buy?

Pfizer released intriguing data regarding its own COVID-19 vaccine.

Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Dynavax Technologies Corporation (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Dynavax Technologies

Co-Diagnostics

Novavax

VBI Vaccines

Bad news about rising COVID-19 cases is good news for these stocks.

Why Novavax, Dynavax, VBI Vaccines, and Co-Diagnostics Stocks Are Jumping Today

Vir Biotechnology

Higher numbers of COVID-19 cases helped these biotechs, which are working on treatments and vaccines for the disease.

Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today

Aeglea BioTherapeutics

Liquidia Technologies Inc

PhaseBio Pharmaceuticals Inc

Seelos Therapeutics

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shorts today.

Top Stocks To Short As Markets Rebound Ignores Disappointing Monday

Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.

Dynavax's Partner Doses First Patient in Coronavirus Study

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%

EMERYVILLE, Calif., June  22, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that  Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:50 a.m. E.T.

Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series

An early-stage clinical study has begun evaluating a COVID-19 vaccine candidate that features Dynavax's adjuvant.

Why Dynavax Shares Are Jumping Today

EMERYVILLE, Calif., June  19, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, announced today that the first participants have been dosed in the Phase 1 clinical trial to evaluate  Clover Biopharmaceuticals ’ vaccine candidate to prevent COVID-19 that contains the Company’s  CpG 1018 adjuvant .

Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant

Corcept Therapeutics

G1 Therapeutics

ImmunoGen

Kadmon Hlds

Supernus Pharmaceuticals

Vertex Pharmaceuticals

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

7 Great Biotech Stocks to Buy and Hold Now

B2Gold

Constellium NV Class A

Identiv

LiveXLive Media

Ovid Therapeutics

Plug Power

Sequans Communications

Vonage Hlds

X4 Pharmaceuticals Inc

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

10 Cheap Stocks to Buy Under $10

Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

EMERYVILLE, Calif., June  09, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has completed enrollment of 119 patients in the clinical trial evaluating  HEPLISAV-B ® [Hepatitis B Vaccine (Recombinant), Adjuvanted] in adults with end-stage renal disease (ESRD) who are initiating or undergoing hemodialysis. The Company anticipates final immunogenicity study data in the fourth quarter of 2020.

Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Last week's momentum continued for the high-flying biotech stock.

Why Dynavax Stock Crushed It Today

Avis Budget Group

Liberty Media Corp-Liberty Formula One

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys: Avis, Dynavax And Formula One

The company's vaccine partner made positive comments about its progress today.

Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes

Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options

Arcturus Therapeutics

iBio

Inovio Pharmaceuticals

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

EMERYVILLE, Calif., May  27, 2020  (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares, at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, were approximately $80.5 million.

Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., May  21, 2020  (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, are expected to be approximately $70.0 million. In addition, Dynavax has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock. The offering is expected to close on or about May 27, 2020, subject to satisfaction of customary closing conditions.

News for Dynavax Technologies Stock (DVAX)